Santa Ana, United States
NKGen Biotech, Inc. is a clinical-stage biotechnology company established in 2017. The startup focuses on enhancing the immune system's natural capabilities by developing innovative autologous, allogeneic, and CAR-NK cell therapies. These are designed to target neurodegenerative and oncological diseases, leveraging their proprietary SNK (super-activated) platform.
The company's mission is to improve patient outcomes safely and naturally with groundbreaking cell therapy products, aspiring to lead globally in immune cell therapeutics. Their slogan, "Maximizing immune integrity through the development of unique natural killer (NK) cell therapies," reflects this commitment.
Currently, NKGen Biotech is poised as an attractive candidate for investment, especially for those interested in cutting-edge biotechnologies aimed at harnessing the immune system's power. Details about the company's headquarters, industries, and latest investment activities are presently undisclosed.
